IL17A and myeloid sarcoma: In recent years, studies have shown the involvement of the Th17/IL-17 pathway in the pathogenesis of both AS and MS [9,10,11]; positive results were obtained after the treatment with secukinumab, a monoclonal antibody that inhibits the activity of IL-17, in patients with both AS and MS [12].